Granite Investment Partners’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$98.5K Buy
18,148
+3,317
+22% +$13.9K 0.01% 259
2026
Q1
$45.5K Buy
+14,831
New +$45.5K ﹤0.01% 252

Other funds holding STLN

Granite Investment Partners's STLN Position: Q2 2026 in Review

Granite Investment Partners increased its Starling Oncology (STLN) stake by 22% in Q2 2026, buying an estimated $13.9K and bringing the position to 18,148 shares worth $98.5K. The position accounts for 0.01% of the portfolio, ranked #259.

Granite Investment Partners first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Granite Investment Partners held 18,148 shares of Starling Oncology worth $98.5K as of Q2 2026.
  • Granite Investment Partners bought 3,317 Starling Oncology shares in Q2 2026, an estimated $13.9K.
  • Starling Oncology made up 0.01% of Granite Investment Partners's portfolio in Q2 2026, its #259 holding.
  • Granite Investment Partners first reported a position in Starling Oncology in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.